当前位置：
X-MOL 学术
›
Natl. Sci. Rev.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
New light on the horizon of Alzheimer's disease
National Science Review ( IF 16.3 ) Pub Date : 2020-05-25 , DOI: 10.1093/nsr/nwaa008 Mu-Ming Poo 1, 2, 3
National Science Review ( IF 16.3 ) Pub Date : 2020-05-25 , DOI: 10.1093/nsr/nwaa008 Mu-Ming Poo 1, 2, 3
Affiliation
The beginning of the year 2020 is marked by a groundbreaking event in drug development in China. A first-in-class drug for Alzheimer's disease (AD), GV-971, received conditional approval by the China Food and Drug Administration for the Chinese market. China now has at least 10 million patients with diagnosed AD, afflicting almost one-third of the population aged 90–94 years. There is increasing demand for new AD drugs, as the societal burden caused by this devastating disease is becoming a major healthcare issue in all aging societies. This urgency is reflected by the conditional approval of the drug, a widely used method by drug regulatory agencies in advanced countries to expedite promising new medicines to the market and facilitate early patient access, before long-term assessment of the treatment is available.
更新日期：2020-05-25
京公网安备 11010802027423号